We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Catalyst, Jacobus Settle Patent Dispute Over LEMS Drug Ruzurgi
Catalyst, Jacobus Settle Patent Dispute Over LEMS Drug Ruzurgi
Catalyst Pharmaceuticals has settled with Jacobus Pharmaceutical over claims that Jacobus’ Lambert-Eaton myasthenic syndrome (LEMS) drug Ruzurgi (amifampridine) infringed on its patent rights for Firdapse (amifampridine).
